SG Americas Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

SG Americas Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-46,700	Closed	-$4K	–	3247
2025 Q4	$4K	Hold	46,700	–	–	﹤0.01%	3544
2025 Q3	$25K	Hold	46,700	–	–	﹤0.01%	3268
2025 Q2	$63K	Hold	46,700	–	–	﹤0.01%	2731
2025 Q1	$398K	Sell	46,700 -10,000	-18%	-$673K	﹤0.01%	1966
2024 Q4	$404K	Buy	+56,700	New	+$3.8M	﹤0.01%	1526
2018 Q1	–	Sell	-71,100	Closed	-$66K	–	3254
2017 Q4	$66K	Hold	71,100	–	–	﹤0.01%	2933
2017 Q3	$334K	Buy	+71,100	New	+$6.28M	﹤0.01%	2146
2017 Q1	–	Sell	-14,000	Closed	-$4K	–	3277
2016 Q4	$4K	Hold	14,000	–	–	﹤0.01%	3048
2016 Q3	$34K	Hold	14,000	–	–	﹤0.01%	3212
2016 Q2	$21K	Hold	14,000	–	–	﹤0.01%	2507
2016 Q1	$49K	Hold	14,000	–	–	﹤0.01%	2767
2015 Q4	$195K	Buy	+14,000	New	+$1.46M	﹤0.01%	2120
2015 Q3	–	Sell	-14,000	Closed	-$489K	–	2123
2015 Q2	$489K	Hold	14,000	–	–	﹤0.01%	1459
2015 Q1	$385K	Buy	+14,000	New	+$1.48M	﹤0.01%	1562

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SG Americas Securities's BMRN Position: Q2 2026 in Review

SG Americas Securities reduced its BioMarin Pharmaceuticals (BMRN) stake by 44% in Q2 2026, selling an estimated $3.5M and leaving 83,024 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1113.

SG Americas Securities first reported a position in BMRN in Q3 2013 and has held it in 50 quarters since. The position peaked at $21.3M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

SG Americas Securities held 83,024 shares of BioMarin Pharmaceuticals worth $4.75M as of Q2 2026.
SG Americas Securities sold 63,939 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $3.5M.
BioMarin Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1113 holding.
SG Americas Securities first reported a position in BioMarin Pharmaceuticals in Q3 2013 and has held it in 50 quarters since.
SG Americas Securities's BioMarin Pharmaceuticals position peaked at $21.3M in Q4 2025.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.